Akeso Past Earnings Performance
Past criteria checks 0/6
Akeso has been growing earnings at an average annual rate of 40.4%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 80.1% per year.
Key information
40.4%
Earnings growth rate
53.4%
EPS growth rate
Biotechs Industry Growth | 11.0% |
Revenue growth rate | 80.1% |
Return on equity | -15.5% |
Net Margin | -39.2% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking
Sep 09Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Aug 30Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment
Jun 24Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding
Jun 19Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?
May 31Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price
Apr 24We Think Akeso's (HKG:9926) Robust Earnings Are Conservative
Mar 25Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Mar 20Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price
Dec 28An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued
Nov 16Is Akeso (HKG:9926) Using Too Much Debt?
Oct 02The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts
Aug 31Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?
Jun 26There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price
May 22Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?
Apr 11Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%
Mar 21An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued
Mar 02Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price
Nov 01Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook
Aug 28Revenue & Expenses Breakdown
How Akeso makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 1,874 | -735 | 1,164 | 1,274 |
31 Mar 24 | 3,200 | 646 | 1,127 | 1,264 |
31 Dec 23 | 4,526 | 2,028 | 1,090 | 1,254 |
30 Sep 23 | 4,439 | 2,008 | 1,071 | 1,278 |
30 Jun 23 | 4,351 | 1,987 | 1,052 | 1,302 |
31 Mar 23 | 2,595 | 409 | 902 | 1,313 |
31 Dec 22 | 838 | -1,168 | 752 | 1,323 |
30 Sep 22 | 549 | -1,224 | 672 | 1,239 |
30 Jun 22 | 260 | -1,280 | 592 | 1,155 |
31 Mar 22 | 243 | -1,178 | 508 | 1,139 |
31 Dec 21 | 226 | -1,075 | 423 | 1,123 |
30 Sep 21 | 177 | -1,002 | 324 | 1,107 |
30 Jun 21 | 129 | -929 | 226 | 1,091 |
31 Mar 21 | 64 | -983 | 240 | 930 |
31 Dec 20 | 0 | -1,036 | 253 | 769 |
30 Sep 20 | 35 | -870 | 197 | 597 |
30 Jun 20 | 71 | -703 | 141 | 426 |
31 Mar 20 | 71 | -492 | 98 | 367 |
31 Dec 19 | 71 | -282 | 55 | 308 |
31 Dec 18 | 3 | -142 | 20 | 161 |
Quality Earnings: 9926 is currently unprofitable.
Growing Profit Margin: 9926 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9926 is unprofitable, but has reduced losses over the past 5 years at a rate of 40.4% per year.
Accelerating Growth: Unable to compare 9926's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9926 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.7%).
Return on Equity
High ROE: 9926 has a negative Return on Equity (-15.49%), as it is currently unprofitable.